



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	63.73
Trade Time:	4:00 PM ET Sep 26, 2017
Change:	-0.64 (-0.994%)
Day Range	62.89 - 64.50
52-Week Range	40.58 - 69.53
Volume	140,016

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 18, 2017*
[Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis](#)
- Aug 15, 2017*
[Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting](#)
- Aug 8, 2017*
[Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update](#)
- Aug 1, 2017*
[Prothena to Report Second Quarter 2017 Financial Results on August 8](#)
- Jul 5, 2017*
[Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 27, 2017*
[Annual Report \(10-K\)](#)
- Mar 31, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)